CD36 inhibition to control obesity and insulin sensitivity
US9283243B2 · kind B2 · utility
0Cited by
5References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2011 |
| Grant date | Mar 15, 2016 |
| Priority date | — |
| Expiry date | Jul 28, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to the therapeutic utility of CD36 antagonists to reduce body weight, inhibit fat accumulation and especially visceral fat accumulation, improve insulin sensitivity, lower blood glucose levels, and treat and prevent metabolic syndrome, pre-diabetes and diabetes, and lower plasma cholesterol levels and decrease fat deposit in the liver. CD36 antagonists, including SAB or its metabolites, such as RA and DSS, are useful for these purposes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.